Back to News
Market Impact: 0.25
Jupiter Neurosciences Starts Phase 2a Parkinson's Trial Of JOTROL
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Jupiter Neurosciences said the first patient has been dosed in its Phase 2a RESET trial evaluating JOTROL in patients with Parkinson's disease. The dosing milestone advances the clinical program, but the report provides no efficacy results or additional trial timing details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
JUNS0.45
More News
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Nvidia Is on the Verge of a $6 Trillion Market Value
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes
- What Marvell's rosy long-term guidance means for our AI chip stocks
- Analysis-Vietnam’s banks tap investors for $7 billion as economy runs red hot
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle